Pharmacokinetic Analysis and In Vitro Synergy Evaluation of Cefiderocol, Sulbactam, and Tigecycline in an Extensively Drug-Resistant <i>Acinetobacter baumannii</i> Pneumonia Patient Receiving Continuous Venovenous Hemodiafiltration-Reference-Cited by-同舟云学术

Pharmacokinetic Analysis and In Vitro Synergy Evaluation of Cefiderocol, Sulbactam, and Tigecycline in an Extensively Drug-Resistant Acinetobacter baumannii Pneumonia Patient Receiving Continuous Venovenous Hemodiafiltration

Published:2022-09-21 Issue:10 Volume:9 Page:
ISSN:2328-8957
Container-title:Open Forum Infectious Diseases
language:en
Short-container-title:

Author:

Kobic Emir¹,Abouelhassan Yasmeen²,Singaravelu Kumara³,Nicolau David P²⁴

Affiliation:

1. Department of Pharmacy, Banner University Medical Center , Phoenix, Arizona , USA

2. Center for Anti-Infective Research and Development, Hartford Hospital , Hartford, Connecticut , USA

3. Division of Infectious Diseases, Banner University Medical Center , Phoenix, Arizona , USA

4. Division of Infectious Diseases, Hartford Hospital , Hartford, Connecticut , USA

Abstract

Abstract Antimicrobial treatments for extensively drug-resistant Acinetobacter baumannii (XDR-AB) infections have proven lackluster, while dosing challenges in patients receiving continuous renal replacement therapy continue. We describe a patient receiving cefiderocol, ampicillin/sulbactam, and tigecycline for XDR-AB while undergoing continuous venovenous hemodiafiltration. The clinical course, cefiderocol and sulbactam pharmacokinetics, and synergy assessments are described.

Publisher

Oxford University Press (OUP)

Subject

Infectious Diseases,Oncology

Link

https://academic.oup.com/ofid/advance-article-pdf/doi/10.1093/ofid/ofac484/45956987/ofac484.pdf

Reference26 articles.

1. Clinical and pathophysiological overview of Acinetobacter infections: a century of challenges;Wong;Clin Microbiol Rev,2017

2. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance;Magiorakos;Clin Microbiol Infect,2012

3. The FDA reboot of antibiotic development;Shlaes;Antimicrob Agents Chemother,2013

4. A descriptive case series of pharmacokinetic/pharmacodynamic target attainment and microbiological outcome in critically ill patients with documented severe extensively drug-resistant Acinetobacter baumannii bloodstream infection and/or ventilator-associated pneumonia treated with cefiderocol;Gatti;J Glob Antimicrob Resist,2021

5. Infectious Diseases Society of America guidance on the treatment of AmpC β-lactamase-producing Enterobacterales, carbapenem-resistant Acinetobacter baumannii, and Stenotrophomonas maltophilia infections;Tamma;Clin Infect Dis,2022

Cited by 6 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Synergistic Activity of Cefiderocol in Combination with Avibactam, Sulbactam or Tazobactam against Carbapenem-Resistant Gram-Negative Bacteria;Cells;2024-08-06

2. Pharmacokinetics/pharmacodynamics of cefiderocol administered by continuous infusion in a case series of critically ill patients with carbapenem-resistant Acinetobacter baumannii infections undergoing continuous venovenous haemodiafiltration (CVVHDF);International Journal of Antimicrobial Agents;2023-08

3. Prospective role of cefiderocol in the management of carbapenem-resistant Acinetobacter baumannii infections: Review of the evidence;International Journal of Antimicrobial Agents;2023-08

4. Treatment of critically ill patients with cefiderocol for infections caused by multidrug-resistant pathogens: review of the evidence;Annals of Intensive Care;2023-06-15

5. Navigating Available Treatment Options for Carbapenem-ResistantAcinetobacter baumannii-calcoaceticusComplex Infections;Clinical Infectious Diseases;2023-05-01